Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$2.26 -0.04 (-1.74%)
(As of 11/20/2024 ET)

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Key Stats

Today's Range
$2.26
$2.30
50-Day Range
$2.17
$2.51
52-Week Range
$2.00
$3.67
Volume
60,933 shs
Average Volume
107,531 shs
Market Capitalization
$91.10 million
P/E Ratio
4.43
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
30th Percentile Overall Score

ORMP MarketRank™: 

Oramed Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat, and ranked 787th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from $0.24 to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is 4.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is 4.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.34.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.74% of the outstanding shares of Oramed Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently increased by 0.50%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Oramed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.74% of the outstanding shares of Oramed Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently increased by 0.50%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Oramed Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oramed Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    Only 7 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

Oramed Pharm (ORMP) Receives a Hold from H.C. Wainwright
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
3 Micro-Cap Moonshots for Fearless Investors
Oramed Letter to Shareholders
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.31 at the start of the year. Since then, ORMP stock has decreased by 2.2% and is now trading at $2.26.
View the best growth stocks for 2024 here
.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.06. The biotechnology company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.70 million.

Oramed Pharmaceuticals' top institutional shareholders include BML Capital Management LLC (5.36%), Murchinson Ltd. (4.24%), Connor Clark & Lunn Investment Management Ltd. (0.27%) and XTX Topco Ltd (0.06%). Insiders that own company stock include Michael Rabinowitz, Nadav Kidron, Yadin Rozov and Kevin Rakin.
View institutional ownership trends
.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
1/10/2022
Today
11/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORMP
Employees
10
Year Founded
N/A

Profitability

Net Income
$5.53 million
Pretax Margin
1,518.25%

Debt

Sales & Book Value

Annual Sales
$1.34 million
Book Value
$4.04 per share

Miscellaneous

Free Float
34,789,000
Market Cap
$91.10 million
Optionable
Optionable
Beta
1.77

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners